Efficacy of clarithromycin containing bismuth-based regimen as a second-line therapy in helicobacter pylori eradication by Mokhtare, Marjan et al.
Middle East Journal of Digestive Diseases/ Vol.7/ No.2/ April 2015
Efficacy of Clarithromycin Containing Bismuth–Based Regimen 
as a Second-Line Therapy in Helicobacter Pylori Eradication
ABSTRACT
BACKGROUND 
The eradication of Helicobacter pylori infection, commonly prevailing in 
the stomach, has been important since its introduction. Adequate preparations 
should be made in finding alternatives when faced with first-line treatment fail-
ures. Currently, ideal second-line treatments are indistinct and varied among 
countries as result of different antibiotic resistance patterns. We aimed to eval-
uate the safety and efficacy of a clarithromycin-containing bismuth-based qua-
druple regimen as a second-line treatment. 
METHODS  
Forty-eight H.pylori-positive patients with proven gastric or duodenal ul-
cers and/or erosions who had previously failed to respond to furazolidone-
containing regimens were enrolled. They received pantoprazole (40 mg-bid), 
amoxicillin (1gr-bid), bismuth subcitrate (240 mg-bid), and clarithromycin 
(500mg-bid) for 10 days. Eight weeks after treatment, a 14C-urea breath test 
was performed for the re-evaluation of H. pylori eradication.  
RESULTS 
Forty-three patients completed the study. H.pylori eradication rates were 
79.2% (95% CI=65.00-89.53) and 88.4% (95% CI=74.91-96.11) according to 
intention-to-treat and per-protocol analyses, respectively. All patients had ex-
cellent compliance to treatment and one did not continue therapy because of 
adverse effects.  
CONCLUSION
In developing countries such as Iran, a ten-day clarithromycin-containing 
bismuth-based quadruple regimen is encouraged as a second-line treatment 
because of the acceptable rate of eradication and low adverse effects.  
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INTRODUCTION
Eradication of Helicobacter pylori infections has currently become 
an important concern because it can cause many gastroduodenal dis-
orders.1 The identification of H.pylori as a gastric pathogen has had 
a significant effect on the gastroenterological practice because many 
untreatable gastroduodenal disorders have become treatable. Eradica-
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tion of H.pylori infection has a considerable effect 
on ulcer healing and can decrease the risk of gastric 
cancer development. 
Only a few antibiotics can be used in vivo to treat 
the infection despite its susceptibility to several 
antibiotics in vitro.2 Standard triple therapy is still 
the first-line therapy; however, when considering 
the Maastricht IV Consensus Report, it should be 
avoided in high clarithromycin resistance areas. The 
options of first-line eradication regimens consist of 
bismuth-containing quadruple regimen, sequen-
tial, concomitant, and hybrid regimens.1 However, 
adequate preparations should be made in finding 
alternatives when faced with first-line treatment 
failures.3 Currently, ideal second-line treatments 
are indistinct and dissimilar among countries due 
to different antibiotic resistance patterns.1 Second-
line therapies that can be recommended at present 
in Asia  include triple regimens that have not been 
prescribed for the patient in the past, bismuth-based 
quadruple regimen, quinolone-based triple regi-
men, and rifabutin-based triple regimen.4
Current guidelines recommend a bismuth-based 
quadruple regimen for 7–10 days for second-line 
therapy, showing eradication rates of 59–95%.5 In 
the event of initial treatment failure, the Maastricht 
conferences recommend using treatments of two 
differing regimens. In other words, a second-line 
therapy choice depends on what was used first-line; 
therefore, it should be constituted of various anti-
biotics based on local antibiotic resistances.6 This 
strategy has had an eradication rate of 99.5%, given 
its proper application.7
Third-line therapy should culture-based in order 
to choose the most effective regimens.1 High an-
timicrobial resistance and poor patient compliance 
are the main causes of H.pylori treatment failure. 
Regarding the different H.pylori prevalence rates 
and different antimicrobial resistance rates in our 
country,8 type and dosage of the drugs and duration 
of treatment should be based on topical review.
According to the results of several studies such 
as the third Brazilian consensus, furazolidone-
containing regimens are recommended as first-
line therapies mainly due to their low cost and 
low resistance.9,10 In Iran, furazolidone, combined 
with amoxicillin, bismuth, metronidazole, and 
a PPI(Proton Pump Inhibitor), are prescribed in 
the form of a quadruple and triple therapy as the 
first-line therapy with different results based on 
the dose and duration of treatment.11,12 This study 
was designed to evaluate the efficacy and safety 
of the quadruple 10-day clarithromycin containing 
bismuth-based regimen for H.pylori eradication as 
a second-line therapy in patients with documented 
peptic ulcer disease or gastroduodenitis. Those in-
cluded in the study had received a furazolidone-
containing regimen as first-line therapy.
MATERIALS AND METHODS
This study was performed at Imam Khomeini 
Hospital, Mazandaran University Teaching Hos-
pital in Sari, north Iran. Forty-eight patients with 
H.pylori positive peptic ulcer disease or gastro-
duodenitis who had been previously treated with 
first line furazolidone-containing regimens were 
enrolled. Omeprazole (20mg-bid), amoxicillin 
(1gr-bid), and furazolidone (200mg bid or tid) were 
administered for 10 days. Patients had all failed 
the above mentioned therapy, and their failure to 
H.pylori eradication regimen was confirmed by 
14C-urea breath test eight weeks after treatment (by 
means of urea composition made by Helicap Insti-
tute of Isotopes, Budapest, Hungary, and a cartridge 
made by Heliprobe breath card, Kibion Uppsala, 
Sweden).
The exclusion criteria were being less than 18 
years old, having severe underlying liver, cardiac, 
pulmonary, or renal diseases, pregnancy, breast-
feeding, any kind of malignancy, previous gastric 
surgery, coagulopathy, having received antibiotics 
or nonsteroidal anti-inflammatory drugs (NSAIDs) 
during the previous 4 weeks, and previous history 
of allergic reactions to any of medications used in 
this protocol. Demographic and endoscopic infor-
mation, history of previous upper gastrointestinal 
bleeding, and smoking habits were also recorded.
All patients received a bismuth-based clar-
ithromycin-containing quadruple therapy (PABC) 
including pantoprazole (40mg-bid), amoxicillin 
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(1gr-bid), bismuth subcitrate (240mg-bid), and clar-
ithromycin (500mg-bid) for ten days. They were 
given written instructions and were informed of the 
treatment modality. Written informed consent was 
also obtained from all the patients. This study was 
approved by the Ethics Committee of Mazandaran 
University of Medical Sciences (code:1077).
During the course of treatment, patients recorded 
the side effects of the medications each day and 
were advised to call the doctor in case of severe 
side effects. After the course of treatment, they 
were visited and asked about their compliance to 
treatment, according to residual pill count and side 
effects of drugs. Their answers were recorded in a 
specific questionnaire. The severity of side effects 
were classified as: No side effect, Mild (not inter-
fering with daily activities), Moderate (partially 
interfering with daily activities), and Severe (aban-
doning daily activities). Compliance to treatment 
was considered “excellent” if the patient had used 
more than 80% of the prescribed drugs, “good” if 
they had used 71-80%, “moderate” if they had used 
60-70%, and “bad” if they had used less than 60%. 
Pantoprazole was continued for patients with 
peptic ulcer disease until 4 weeks after completion 
of the eradication regimen. Eight weeks after the 
present treatment course, H.pylorii eradication was 
reassessed using 14C-urea breath test (UBT). All pa-
tients were advised to discontinue proton-pump in-
hibitors for at least 2 weeks before the UBT. For the 
UBT, patients swallowed 37 kBq (1 lCi) of encap-
sulated 14C-labled urea composition (Helicap Insti-
tute of Isotopes, Budapest, Hungary) with water. 
After 10 minutes, patients exhaled into a cartridge 
(Heliprobe breath card, Kibion Uppsala, Sweden) 
until the indicator of the card changed from orange 
to yellow. The cards were inserted into a Geiger 
Muller counter (Heliprobe Analyser, Kibion AB, 
Uppsala, Sweden), and radioactivity of samples 
was automatically measured after 250 seconds. 
Based on radioactivity as count per minute (cpm), 
counts of more than 50 cpm were considered in-
fected with H.pylori.
Data were analyzed using SPSS software, ver-
sion 13. For the calculation of the intention-to-treat 
eradication rate, all the patients who entered the 
study were considered. To calculate the per-proto-
col eradication rate, only those who completed the 
entire protocol with more than 80% compliance 
(according to the residual pill count) were consid-
ered for analysis. Fisher’s exact test was also used 
as appropriated. p<0.05 were considered statisti-
cally significant.
 
RESULTS
Among the participants, 30 (62.5%) patients 
were men. The mean±SD age of the participants 
was 43.75±13.98 years (range: 21-68 years). Seven 
(14.6%) patients were smokers, and 5 (10.4%) pa-
tients had a previous history of upper gastrointes-
tinal bleeding. The demographic and endoscopic 
findings of the patients are shown in table 1.
Forty-three (97.74%) patients completed the 
study with excellent compliance. One (2.27%) pa-
tient’s regimen was interrupted due to intolerable 
adverse effects, nausea, and vomiting. Four patients 
were lost at follow-up; two were lost due to other 
medical problems, and two failed to follow-up. 
H.pylori eradication rates were 79.2% (95% 
CI=65.00-89.53) and 88.4% (95% CI=74.91-96.11) 
according to an intention-to-treat and per-protocol 
analysis, respectively (flowchart 1). 
None of the base-line demographic variables or 
endoscopic findings was associated with UBT re-
sults, according to Fisher’s exact test.
Twenty-two (51.2%) patients complained of ad-
verse effects after therapy (table 2), the most com-
mon being bitter taste (43.8%). Side effects were 
mild in 17 (39.5%) patients, moderate in 4(9.3%), 
and severe in 1(2.3%). Adverse reactions mostly 
occurred during the first five days of treatment in 
12 of the 22 patients(table 3).
DISCUSSION
Standard triple therapy is still the first-line ther-
apy; however, when considering the Maastricht IV 
Consensus Report, it should be avoided in high 
clarithromycin resistance areas. Options of first-
line eradication regimens contain bismuth-based 
quadruple regimen, sequential, concomitant, and 
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hybrid regimens.1 Quinolone-based triple regimen 
may be a good alternative as first-line therapy in 
areas of clarithromycin resistance of >15–20% 
and quinolone resistance of <10%.1 In developing 
countries such as Iran, furazolidone has also been 
used in first-line eradication regimens due to its low 
cost, drug resistance, and high efficacy. It serves 
as an alternative for clarithromycin or metronida-
zole, which have shown an increase in resistance in 
Iran.11 Meanwhile, adequate preparations should be 
made in finding alternatives when faced with first-
line treatment failures.3 Currently, ideal second-line 
treatments are indistinct and usually differ from 
country to country due to different antibiotic re-
sistance patterns.1 For example, the prevalence of 
clarithromycin resistant strains was 29.3%, 18.9%, 
and 11.1% in the United States, Asia, and Europe, 
respectively.13 There appears to be an increasing 
rate of resistance to clarithromycin and metronida-
zole in parts of Asia, leading to reduced efficacy of 
PPI-based triple therapy.4
Primary resistance to antibiotics is about 26.7% 
for metronidazole, 11.2% for amoxicillin, 17.2% 
for clarithromycin, 5.9% for tetracycline, and 
16.2% for levofloxacin across Asia.13 In Iran, the re-
sistance rates of H.pylori to clarithromycin, amoxi-
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Table 1: The patients demographic and endoscopic findings 
PABC 
N (%)
Included by ITT analysis(n) 48
Male / female (n) 30/18
Mean age ± SD 43.75±13.98
Current Smoking 7(14.6)
History of GIB 5(10.4)
Endoscopic findings
DU 27(56.3)
GU 8(16.7)
GE+DE 13(27.1)
Bulb  deformity 9(18.8)
Number of patients completed the study (PP 
analysis)
43
PABC=Pantoprazole, Amoxicillin, Bismuth subcitrate, Clar-
ithromycin, ITT=Intention-to-treat, SD=standard deviation, 
GIB=Gastrointestinal bleeding, DU=Duodenal ulcer, GU=Gastric 
ulcer, DE=Duodenal erosions, GE=Gastric erosions, PP=per-pro-
tocol
Table 2: Side effects of therapy reported by the patients
Side effects Frequency  N (%)
Bad taste 21(43.8)
Nausea 9(18.8)
Abdominal pain 8(16.7)
Dry Mouth  5(10.4)
Diarrhea 4(8.3)
Dizziness 4(8.3)
Burning sensation of tongue 3(6.3)
Weakness 2(4.2)
Anorexia 2(4.2)
Vomiting 2(4.2)
Constipation 1(2.1)
Headache 1(2.1)
Total enrolled patients, PABC 
Regimen (N=48)
Intention-to-treat 
efficacy=79.2%
Unevaluable=5
Lost follow up=4
Discontinue medication due to 
adverse effect=1
Completed=43
Per-Protocol Efficacy=88.4%
Flowchart 1: Method of follow-up and treatment efficacy
Table 3: Prevalence of mild, moderate, and severe drug 
adverse effects
Severity of side effects N(%)
None 21(48.8)
Mild 17(39.5)
Moderate 4(9.3)
Severe 1(2.3)
Drug withdrawal due to severe side effects 1
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cillin, and furazolidone are 7.3%, 7.3%, and 4.5%, 
respectively. Additionally, the resistance to metro-
nidazole is 55.6% and 38.1% to tetracycline.14,15
The main causes of H.pylori treatment failure are 
high antimicrobial resistance and poor patient com-
pliance; however, other factors including a high 
bacterial load and low gastric PH must also be con-
sidered.5 Antibiotic resistance to different antimi-
crobials is considered the major reason for H.pylori 
treatment failure when considering the extremely 
high rate of H.pylori infection (more than 80%) in 
Iran.16 However, there is debate whether antibiotic 
susceptibility testing should be implemented when 
first-line eradication fails. This is because even 
though such testing has been shown to enhance 
eradication rates, the test’s high price implies that 
its availability will not be consistent. Generally, 
this measure is considered unnecessary for most pa-
tients and may delay the treatment for patients with 
H.pylori-related peptic ulcer disease.17,18 Since our 
patients had peptic ulcer disease, we initiated sec-
ond-line therapy without performing culture. This 
was carried out according to the primary antibiotic 
resistance patterns in Iran.14,15
In the eradication of H.pylori, it is wise to keep 
in mind the high incidence of treatment-related side 
effects, such as dysgensia with a metallic and/or 
bad taste, diarrhea, nausea, and epigastric discom-
fort, due to the alteration of the intestinal micro-
biota as a result of antibiotic use.19 These adverse 
effects can decrease patient compliance. The ideal 
substitute regimen should contain a short-term and 
simple drug combination including susceptible 
agents, assuring good compliance and low toxicity. 
The regimens used in our study have low side ef-
fects similarly to those of other studies.5 Nowadays 
safe and effective empirical protocols are of great 
need.18
Stomach acidity might affect the stabilization of ac-
id-labile antibiotics, such as clarithromycin.1 It is still 
doubtful whether genotyping of CYP2C19 should be 
performed prior to starting second-line therapy. The 
Second Asia-Pacific consensus does not recommend 
it because of the cost and low availability.4
A number of regimens that overcome bacterial 
resistance to standard antibiotics and have lesser 
adverse effects were assessed in recent years. Sec-
ond-generation fluoroquinolones (levofloxacin, 
moxifloxacin)-based regimens have been assessed 
as either first-line or rescue therapies.14 Moxifloxa-
cin-based triple regimens displayed higher eradica-
tion rates.20 Another study reported that moxiflox-
acin-based triple therapy was an equally or more 
effective and a more tolerable second-line eradi-
cation protocol for H.pylori when compared with 
conventional bismuth-based quadruple therapy.21
Similar efficacy has been shown by levofloxa-
cin-based triple therapy, which has a lower rate of 
adverse effects compared with bismuth-based regi-
mens. Nevertheless, increasing resistance towards 
levofloxacin should be considered.18,22  At present, 
levofloxacin is very expensive in Iran; therefore, 
only a few studies have been able to evaluate its ef-
fects on the eradication of H.pylori in this country.14
The synergistic effects of bismuth salt are exert-
ed by destroying bacteria similar to an antibiotic; 
thus, we included this agent in the second-line regi-
men to increase the effects of other antibiotics.5
Current guidelines recommend a bismuth-based 
quadruple regimen for 7–10 days for the second-
line therapy, showing eradication rates of 59–95%.5 
In the event of failure in the initial treatment, the 
Maastricht conferences have recommended the use 
of treatments consisting of two different regimens 
designed such that a second-line therapy choice 
depending on what was used as a first-line; there-
fore, it should constitute various antibiotics. Such 
recommendations are built upon a knowledge that 
acquired bacterial resistance to metronidazole or 
clarithromycin is chiefly from the previous treat-
ment failure.23 It is fundamentally known that when 
first-line therapy is unsuccessful, the same antibi-
otics should not be re-administered. Studies have 
reported that amoxicillin can be “reused” as the re-
sistance rates are small across the globe.17
Success rates of 99.5% in eradication have been 
reported by means of using this strategy when ac-
curately applied in H.pylori-positive patients.7 An 
eradication rate of 90% is the least accepted rate of 
eradication in second-line therapy.24 In our previous 
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study of first-line treatment, the intention-to-treat 
and per-protocol eradication rates were 76.19% and 
81.63%  in group OAF-400mg  and 80.95%  and 
89.47%  in group OAF-600mg, respectively.12 In 
another study that we conducted on first-line treat-
ment, the intention-to-treat and per-protocol eradi-
cation rates were 84.6% and 90.5% for OAF-600 
mg, respectively.11
It was according to this concept that we switched 
furazolidone, with a low primary resistance rate, to 
clarithromycin and used pantoprazole 40 mg bid in-
stead of omeprazole 20 mg bid. Bismuth was also 
added to the rescue regimen in this study and ob-
tained 79.2% and 88.4% intention-to-treat and per-
protocol eradication rates, respectively.
A recent study on a fourteen-day OABC regimen 
showed the same drug dosage as our study except 
for omeprazole (20 mg bid) as the second-line ther-
apy.5 In their study, clarithromycin was used instead 
of metronidazole. The intention-to-treat and per-
protocol rates were 64.5% and 74.7%, respectively. 
It seems that the use of clarithromycin instead of 
metronidazole, with a high primary resistance rate, 
lowered the eradication rate of the above mentioned 
study’s second-line treatment. 
However, culture and antibiotic susceptibility 
tests appear to be useful in the selection of a third-
line therapy since empirical therapies have dis-
played sub-optimal results.7,17 Microbial culture is, 
conversely, pricey, invasive, and only available in a 
few specific and/or research centers.7
Among the limitations of our study was that an 
evaluation of antibiotic resistance and an investiga-
tion of its relation to eradication rates did not take 
place. In clinical practice, however, there remains 
controversy regarding the efficacy of susceptibility 
testing before second-line therapy.
The H.pylori culture rate is <60% with rate vari-
ation in different institutions and various regions. 
Since this was a study carried out in a clinical set-
ting, we assumed that by performing susceptibility 
testing, the results of the study would have been 
less applicable to what happens at an everyday 
gastroenterology outpatient clinic. Furthermore, in 
vitro drug-resistance cannot always predict in-vivo 
non-response to treatment.1,5,14
The second limitation of this study was the use 
of a single laboratory test to evaluate eradication, 
which could have formed false positive results. 
However, with the known sensitivity and specific-
ity of the 14C-urea breath test, the risk of overesti-
mation was at an acceptable range.21
The third limitation of the study was its small 
sample size.
A clarithromycin containing bismuth-based regi-
men had good efficacy with an 88.4% per-protocol 
eradication rate. The regimen had little side effects, 
and we recommend it as a second-line therapy, es-
pecially if furazolidone containing treatments fail.
CONFLICT OF INTEREST 
   The authors declare no conflict of interest related to 
this work.
REFERENCES
1. Tzung-Shiun Wu, Huang-Ming Hu, Fu-Chen Kuo, Kuo 
C-H. Eradication of Helicobacter pylori infection. Kaohsi-
ung J Med Sci 2014;30:167-72.
2. Monique M Gerrits , Arnoud HM van Vliet, Ernst J Kui-
pers, Kusters JG. Helicobacter pyloriand antimicrobial re-
sistance: molecular mechanisms and clinical implications. 
Lancet Infect Dis 2006;6:699-709.
3. Gisbert JP.  Rescue Therapy for Helicobacter pylori Infec-
tion 2012. Gastroenterol Res Pract 2012;2012:974594.
4. Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, Tal-
ley NJ, et al. Second Asia-Pacific Consensus Guidelines 
for Helicobacter pylori infection. J Gastroenterol Hepatol 
2009;24:1587-600.
5. Minakari M, Davarpanah Jazi AH, Shavakhi A, Mogharea-
bed N, Fatahi F. A Randomized Controlled Trial :Effica-
cy and Safety of Azithromycin, Ofloxacin,Bismuth, and 
Omeprazole Compared With Amoxicillin,Clarithromycin, 
Bismuth , and Omeprazole as Second-Line Therapy in 
Patients With Helocobacter pylori Infection. Helicobacter  
2010;15:154-9.
6. Manfredi M, Bizzarri B, Manzali E, Fugazza Al, Gismondi 
P, de’Angelis GL. Which Treatment in Helicobacter pylori 
Infection?  Clin  Exp Pharmacol 2013;3-4.
7. Roccarina D, Franceschi F, Zocco MA, Garcovich M, Gas-
barrini G, Gasbarrini A. Different Antibiotic No Culture 
Eradicating (DANCE) strategy: An easy way to manage H. 
pylori eradication. Dig Liver Dis 2012;44:889-92.
8. Mohammadi M, Doroud D, Mohajerani N, Massarrat S. 
80 Clarithromycin and Helicobacter Pylori Eradication
Middle East Journal of Digestive Diseases/ Vol.7/ No.2/ April 2015
Helicobacter pylori antibiotic resistance in Iran. World J 
Gastroenterol 2005;11:6009-13.
9. Coelho LG, Maguinilk I, Zaterka S, Parente JM, do Carmo 
Friche Passos M, Moraes-Filho JP. 3rd Brazilian Consen-
sus on Helicobacter pylori. Arq Gastroenterol 2013;50.
10. Riahizadeh S, Malekzadeh R, Agah S, Zendehdel N, So-
toudehmanesh R, Ebrahimi-Dariani N, et al. Sequential 
metronidazole-furazolidone or clarithromycin-furazoli-
done compared to clarithromycin-based quadruple regi-
mens for the eradication of Helicobacter pylori in peptic 
ulcer disease: a double-blind randomized controlled trial. 
Helicobacter 2010;15:497-504.
11. Mokhtare M, Hosseini V, Tirgar Fakheri Hafez H, Maleki I, 
Taghvaei T, Valizadeh SM, et al. Comparison of Quadruple 
and Triple Furazolidone Containing Regimens on Eradica-
tion of Helicobacter Pylori. Med J Islamic Republic Iran 
2014;19.
12. Hosseini V, Mokhtare M, Gholami M, Taghvaei T, Maleki 
I, Valizadeh M, et al. A Comparison between Moderate- 
and High-dose Furazolidone in Triple Regimens for Heli-
cobacterpylori Eradication in Iran. Middle East J Dig Dis 
2014;6:195-202.
13. De Francesco V, Giorgio F, Hassan C, Manes G, Van-
nella L, Panella C, et al. Worldwide H. pylori antibiotic 
resistance: a systematic review. J Gastrointestin Liver Dis 
2010;19:409-14.
14. Fakheri H, Bari Z, Sardarian H. A modified bismuth-based 
quadruple therapy containing a short course of furazoli-
done for Helicobacter pylori  eradication after sequential 
therapy failure. Helicobacter 2012;17:264-8.
15. Siavoshi F, Saniee P, Latifi-Navid S, Massarrat S, Sheyk-
holeslami A.. Increase in resistance rates of H. pylori iso-
lates to metronidazole and tetracycline--comparison of 
three 3-year studies. Arch Iran Med 2010;13:177-87.
16. Khademi F, Faghri J, Poursina F, Esfahani BN, Moghim S, 
Fazeli H, et al. Resistance pattern of Helicobacter pylori 
strains to clarithromycin, metronidazole, and amoxicillin in 
Isfahan, Iran. J Res Med Sci 2013;18:1056-60.
17. Song M, Ang TL. Second and third line treatment options 
forHelicobacter pylori eradication. World J Gastroenterol 
2014;20:1517-28.
18. Gisbert JP, Morena F. Systematic review and meta-
analysis:levofloxacin-based rescue regimens after Helico-
bacter pylori treatment failure. Aliment Pharmacol Ther 
2006;23:35-44.
19. Manfredi M, Bizzarri B, Sacchero RI, Maccari S, Cal-
abrese L, Fabbian F, et al. Helicobacter pylori infection in 
clinical practice: probiotics and a combination of probiot-
ics + lactoferrin improve compliance, but not eradication, 
in sequential therapy. Helicobacter  2012;17:254-63.
20. Bago P, Vcev A, Tomic M, Rozankovic M, Marusić M, 
Bago J. High eradication rate of H. Pylori with moxiflox-
acin-based treatment: a randomized controlled trial. Wien 
Klin Wochenschr 2007;119:372-8.
21. Bago J, Pevec B, Tomić M, Marusić M, Bakula V, Bago 
P. Second-line treatment for Helicobacter pylori infection 
based on moxifloxacin triple therapy: a randomized con-
trolled trial. Wien Klin Wochenschr 2009;121:47-52.
22. Kuo CH, Hu HM, Kuo FC, Hsu PI, Chen A, Yu FJ, et 
al. Efficacy of levofloxacin-based rescue therapy for He-
licobacter pylori infection after standard triple therapy: 
a randomized controlled trial. J Antimicrob Chemother 
2009;63:1017-24.
23. Megraud F. Helicobacter pylori and antibiotic resistance. 
Gut 2007;56:1502.
24. Graham DY, Calvet X. Guide regarding choice of second-
line therapy to obtain a high cumulative cure rate. Helico-
bacter 2012;17:243-5.
81Mokhtare  et al. 
